|Dr. Nassim Usman Ph.D.||Pres, CEO & Director||1.75M||N/A||1960|
|Ms. Seline E. Miller CPA||Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer||707.55k||N/A||1969|
|Ms. Ana Kapor||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.